trending Market Intelligence /marketintelligence/en/news-insights/trending/PklnXCKGZJm5jBL7Ht-I1Q2 content esgSubNav
In This List

Horizon Pharma secures preliminary patent approval for urea disorder drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Horizon Pharma secures preliminary patent approval for urea disorder drug

Horizon Pharma PLC secured preliminary approval for a U.S. patent that would cover its Ravicti oral treatment for urea cycle disorders in patients older than two years of age.

The U.S. Patent and Trademark Office issued a notice of allowance for the patent that would expire on Sept. 22, 2030, once granted.